ZA200102566B - Novel salts of pyridopyrazine compound and crystals thereof. - Google Patents
Novel salts of pyridopyrazine compound and crystals thereof. Download PDFInfo
- Publication number
- ZA200102566B ZA200102566B ZA200102566A ZA200102566A ZA200102566B ZA 200102566 B ZA200102566 B ZA 200102566B ZA 200102566 A ZA200102566 A ZA 200102566A ZA 200102566 A ZA200102566 A ZA 200102566A ZA 200102566 B ZA200102566 B ZA 200102566B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitory activity
- production inhibitory
- compound
- composition
- substance
- Prior art date
Links
- 239000013078 crystal Chemical class 0.000 title claims description 116
- -1 pyridopyrazine compound Chemical class 0.000 title claims description 8
- 150000003839 salts Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 78
- 230000002401 inhibitory effect Effects 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 38
- 230000016396 cytokine production Effects 0.000 claims description 25
- 208000006454 hepatitis Diseases 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 16
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 16
- 239000013256 coordination polymer Substances 0.000 claims description 16
- 231100000283 hepatitis Toxicity 0.000 claims description 16
- 230000008595 infiltration Effects 0.000 claims description 16
- 238000001764 infiltration Methods 0.000 claims description 15
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 15
- 230000005070 ripening Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- LITNEAPWQHVPOK-FFSVYQOJSA-N 2(1h)-pyrimidinone, 5-[3-[(1s,2s,4r)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro- Chemical compound C1=C(O[C@@H]2[C@H]3CC[C@H](C3)C2)C(OC)=CC=C1C1CNC(=O)NC1 LITNEAPWQHVPOK-FFSVYQOJSA-N 0.000 claims description 6
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 206010003645 Atopy Diseases 0.000 claims description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 4
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims description 4
- 229950005741 rolipram Drugs 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- MFKZGAAAKCDLHM-UHFFFAOYSA-N 1-cyclopentyl-6-(3-ethoxypyridin-4-yl)-3-ethyl-5H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound CCOC1=CN=CC=C1C(N1)=NC(=O)C2=C1N(C1CCCC1)N=C2CC MFKZGAAAKCDLHM-UHFFFAOYSA-N 0.000 claims description 3
- DDYUBCCTNHWSQM-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 DDYUBCCTNHWSQM-UHFFFAOYSA-N 0.000 claims description 3
- MNHXYNNKDDXKNP-UHFFFAOYSA-N 4-(3-chlorophenyl)-1,7-diethyl-2-pyrido[2,3-d]pyrimidinone Chemical compound N=1C(=O)N(CC)C2=NC(CC)=CC=C2C=1C1=CC=CC(Cl)=C1 MNHXYNNKDDXKNP-UHFFFAOYSA-N 0.000 claims description 3
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 206010020843 Hyperthermia Diseases 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 208000005374 Poisoning Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- GHBUMWHHZFGRDI-AWEZNQCLSA-N [(3s)-1-(3,5-dimethoxyphenyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-3-yl]methanol Chemical compound COC1=CC(OC)=CC(C=2C3=CC(OC)=C(OC)C=C3C[C@@H](CO)N=2)=C1 GHBUMWHHZFGRDI-AWEZNQCLSA-N 0.000 claims description 3
- 229950009746 arofylline Drugs 0.000 claims description 3
- 229950006944 atizoram Drugs 0.000 claims description 3
- KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 claims description 3
- 229950002405 cipamfylline Drugs 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- STTRYQAGHGJXJJ-LICLKQGHSA-N filaminast Chemical compound COC1=CC=C(C(\C)=N\OC(N)=O)C=C1OC1CCCC1 STTRYQAGHGJXJJ-LICLKQGHSA-N 0.000 claims description 3
- 229950006884 filaminast Drugs 0.000 claims description 3
- ZGEYQGVDCVQKIF-UHFFFAOYSA-N hydron;n'-hydroxy-5,6-dimethoxy-2,3-dihydro-1h-indene-2-carboximidamide;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC2=C1CC(C(\N)=N/O)C2 ZGEYQGVDCVQKIF-UHFFFAOYSA-N 0.000 claims description 3
- 230000036031 hyperthermia Effects 0.000 claims description 3
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- FVZJIAUYFDQQKJ-DQEYMECFSA-N n-[4-[(4as,10br)-8,9-dimethoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]phenyl]-4-methylbenzenesulfonamide Chemical compound N([C@H]1CCN(C)C[C@H]1C=1C=C(C(=CC=11)OC)OC)=C1C(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(C)C=C1 FVZJIAUYFDQQKJ-DQEYMECFSA-N 0.000 claims description 3
- 238000012753 partial hepatectomy Methods 0.000 claims description 3
- 229950005184 piclamilast Drugs 0.000 claims description 3
- 231100000572 poisoning Toxicity 0.000 claims description 3
- 230000000607 poisoning effect Effects 0.000 claims description 3
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims description 3
- 229960002586 roflumilast Drugs 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 229950010448 tolafentrine Drugs 0.000 claims description 3
- 206010044325 trachoma Diseases 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- HJMQDJPMQIHLPB-UHFFFAOYSA-N zardaverine Chemical compound C1=C(OC(F)F)C(OC)=CC(C2=NNC(=O)C=C2)=C1 HJMQDJPMQIHLPB-UHFFFAOYSA-N 0.000 claims description 3
- 229950001080 zardaverine Drugs 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 241001420836 Ophthalmitis Species 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- DVWBMWJOYIFITF-UHFFFAOYSA-N n'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC2=C1SC(C(\N)=N\O)=C2 DVWBMWJOYIFITF-UHFFFAOYSA-N 0.000 claims description 2
- 208000010403 panophthalmitis Diseases 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 230000006433 tumor necrosis factor production Effects 0.000 claims 11
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 2
- 230000002440 hepatic effect Effects 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- MDBPFVSVLGYVCQ-UHFFFAOYSA-N n-(4-fluorophenyl)-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)NC1=CC=C(F)C=C1 MDBPFVSVLGYVCQ-UHFFFAOYSA-N 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 102100025168 Calpain-15 Human genes 0.000 claims 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 1
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 101000934071 Homo sapiens Calpain-15 Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008865 drug-induced hepatitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 20
- 238000001914 filtration Methods 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000012458 free base Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 210000004969 inflammatory cell Anatomy 0.000 description 13
- 239000000523 sample Substances 0.000 description 10
- 231100000832 liver cell necrosis Toxicity 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- XZXLYGAUEAPJET-UHFFFAOYSA-N 5-amino-3h-1-benzofuran-2-one Chemical compound NC1=CC=C2OC(=O)CC2=C1 XZXLYGAUEAPJET-UHFFFAOYSA-N 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 238000013329 compounding Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 210000003979 eosinophil Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229910017053 inorganic salt Inorganic materials 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- ABTMACKEHUIEPX-UHFFFAOYSA-N n-[3-[(3-nitropyridin-2-yl)amino]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(NC=2C(=CC=CN=2)[N+]([O-])=O)=C1 ABTMACKEHUIEPX-UHFFFAOYSA-N 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- LKSPPMDGPWNMMN-UHFFFAOYSA-N 3-n-(3-nitropyridin-2-yl)benzene-1,3-diamine Chemical compound NC1=CC=CC(NC=2C(=CC=CN=2)[N+]([O-])=O)=C1 LKSPPMDGPWNMMN-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 101150015280 Cel gene Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011597 hartley guinea pig Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UUOLETYDNTVQDY-UHFFFAOYSA-N 2-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1Cl UUOLETYDNTVQDY-UHFFFAOYSA-N 0.000 description 1
- VJJMVYPGUCWMQM-UHFFFAOYSA-N 2-oxo-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)C(=O)CC1=CC=CN=C1 VJJMVYPGUCWMQM-UHFFFAOYSA-N 0.000 description 1
- GGHLXLVPNZMBQR-UHFFFAOYSA-N 3,5-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC(Cl)=CC(Cl)=C1 GGHLXLVPNZMBQR-UHFFFAOYSA-N 0.000 description 1
- HKNNERRQSVWCFL-UHFFFAOYSA-N 3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C=N[CH]1 HKNNERRQSVWCFL-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000134916 Amanita Species 0.000 description 1
- 206010004664 Biliary fibrosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102000044708 Eosinophil peroxidases Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010058991 Hepatic vein occlusion Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000001907 Mushroom Poisoning Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- BGCNBOFPABQGNG-UHFFFAOYSA-N ethyl 2-(dimethylamino)acetate Chemical compound CCOC(=O)CN(C)C BGCNBOFPABQGNG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000004434 industrial solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 231100000824 inhalation exposure Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000022023 interleukin-5 production Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 description 1
- UAAKJEVCDBPTQS-UHFFFAOYSA-N methanesulfonic acid;dihydrate Chemical compound O.O.CS(O)(=O)=O UAAKJEVCDBPTQS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- PEMGGJDINLGTON-UHFFFAOYSA-N n-(3-aminophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(N)=C1 PEMGGJDINLGTON-UHFFFAOYSA-N 0.000 description 1
- DBMDUQWYBBRSTN-UHFFFAOYSA-N n-[3-[(3-aminopyridin-2-yl)amino]phenyl]-3,5-dichlorobenzamide Chemical compound NC1=CC=CN=C1NC1=CC=CC(NC(=O)C=2C=C(Cl)C=C(Cl)C=2)=C1 DBMDUQWYBBRSTN-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27444098 | 1998-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200102566B true ZA200102566B (en) | 2002-07-18 |
Family
ID=17541719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200102566A ZA200102566B (en) | 1998-09-29 | 2001-03-28 | Novel salts of pyridopyrazine compound and crystals thereof. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1118615A4 (fr) |
KR (1) | KR20010075287A (fr) |
CN (1) | CN1328555A (fr) |
AU (1) | AU5758199A (fr) |
BR (1) | BR9914399A (fr) |
CA (1) | CA2345362A1 (fr) |
CZ (1) | CZ20011164A3 (fr) |
HK (1) | HK1042896A1 (fr) |
HU (1) | HUP0103947A3 (fr) |
IL (1) | IL142147A0 (fr) |
TR (2) | TR200200971T2 (fr) |
WO (1) | WO2000018768A1 (fr) |
ZA (1) | ZA200102566B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
EP1511516B1 (fr) * | 2002-05-28 | 2008-12-17 | Nycomed GmbH | Preparation pharmaceutique topique |
JP2006501269A (ja) * | 2002-09-16 | 2006-01-12 | アルコン マニュファクチャリング,リミティド | 血管新生を処置するためのpdeivインヒビターの使用 |
EA009985B1 (ru) | 2003-03-10 | 2008-04-28 | Никомед Гмбх | Новый способ получения рофлумиласта |
CA2601250C (fr) | 2005-03-16 | 2014-10-28 | Nycomed Gmbh | Forme posologique a gout masque |
KR20120073300A (ko) * | 2009-09-30 | 2012-07-04 | 뗑따마르 에스아에스 | 휴대 가방 또는 조끼 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0008864A1 (fr) * | 1978-08-15 | 1980-03-19 | FISONS plc | Dérivés de la pyridopyrazine et de la quinoxaline, procédés pour leur préparation, et compositions pharmaceutiques les contenant |
AU594512B2 (en) * | 1986-09-16 | 1990-03-08 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Hydroxy indole derivatives |
GB9413975D0 (en) * | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
-
1999
- 1999-09-22 TR TR2002/00971T patent/TR200200971T2/xx unknown
- 1999-09-22 WO PCT/JP1999/005182 patent/WO2000018768A1/fr not_active Application Discontinuation
- 1999-09-22 AU AU57581/99A patent/AU5758199A/en not_active Abandoned
- 1999-09-22 BR BR9914399-2A patent/BR9914399A/pt not_active IP Right Cessation
- 1999-09-22 KR KR1020017003667A patent/KR20010075287A/ko not_active Application Discontinuation
- 1999-09-22 CA CA002345362A patent/CA2345362A1/fr not_active Abandoned
- 1999-09-22 IL IL14214799A patent/IL142147A0/xx unknown
- 1999-09-22 EP EP99944776A patent/EP1118615A4/fr not_active Withdrawn
- 1999-09-22 CN CN99813617A patent/CN1328555A/zh active Pending
- 1999-09-22 HU HU0103947A patent/HUP0103947A3/hu unknown
- 1999-09-22 TR TR2001/00893T patent/TR200100893T2/xx unknown
- 1999-09-22 CZ CZ20011164A patent/CZ20011164A3/cs unknown
-
2001
- 2001-03-28 ZA ZA200102566A patent/ZA200102566B/en unknown
-
2002
- 2002-06-11 HK HK02104375.5A patent/HK1042896A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN1328555A (zh) | 2001-12-26 |
WO2000018768A1 (fr) | 2000-04-06 |
EP1118615A4 (fr) | 2002-02-27 |
BR9914399A (pt) | 2002-01-22 |
CA2345362A1 (fr) | 2000-04-06 |
HUP0103947A3 (en) | 2002-06-28 |
KR20010075287A (ko) | 2001-08-09 |
HUP0103947A2 (hu) | 2002-04-29 |
IL142147A0 (en) | 2002-03-10 |
EP1118615A1 (fr) | 2001-07-25 |
HK1042896A1 (zh) | 2002-08-30 |
AU5758199A (en) | 2000-04-17 |
TR200100893T2 (tr) | 2001-11-21 |
CZ20011164A3 (cs) | 2001-12-12 |
TR200200971T2 (tr) | 2002-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994022872A1 (fr) | Inhibiteur d'adhesion cellulaire et compose a base de thienotriazolodiazepine | |
JP2001520645A (ja) | 新規な化合物 | |
JP3122792B2 (ja) | 新規な活性化合物 | |
EP2168576A2 (fr) | Nouveaux utilitaires de composés tricycliques | |
WO2002066447A1 (fr) | Derives de 4h-1,2,4-triazole-3(2h)-thione tenant lieu d'inhibiteurs de sphingomyelinase | |
JPWO2003051876A1 (ja) | ピラゾロピリジン誘導体およびその医薬用途 | |
JP2002517499A (ja) | ピロール誘導体、製造方法およびそれを含有する製薬学的組成物 | |
JP2002020386A (ja) | ピラゾロピリジン誘導体 | |
ZA200102566B (en) | Novel salts of pyridopyrazine compound and crystals thereof. | |
JPH035457A (ja) | 新規アリールスルホンアミド、それを含む医薬組成物及びその製造法 | |
WO2017198179A1 (fr) | Applications d'un nouveau dérivé de thiazole dans le traitement d'affections intestinales inflammatoires | |
US7371864B2 (en) | Crystalline forms of a factor Xa inhibitor | |
CA2177146C (fr) | Derives de benzenesulfonylimine heterocycliques en tant qu'inhibiteurs de l'action d'il-1 | |
JP2002544270A (ja) | ベンゾフラニルスルホネート類 | |
CA2582223A1 (fr) | Formes cristallines d'inhibiteur de facteur xa pyrazolo '3, 4-c pyridi ne | |
JPH0662608B2 (ja) | カルボスチリル誘導体 | |
JP2002528541A (ja) | Tnfおよびpde−iv阻害活性を有する複素環式化合物のn−オキシド | |
MXPA01003267A (en) | Novel salts of pyridopyrazine compound and crystals thereof | |
CA2419838A1 (fr) | Inhibiteurs de l'apoptose des cellules du muscle cardiaque et agents therapeutiques/prophylactiques contre les maladies cardiaques | |
US5710164A (en) | Diheterocyclic styryl nitriles | |
JPH07101941A (ja) | 2−[2−(置換アミノ)ベンジルチオ]−5,6, 7,8−テトラヒドロ−4(3h)−キナゾリノン誘 導体 | |
JP2001181186A (ja) | ピリド[4,3−b][1,6]ナフチリジン誘導体を有効成分として含有する肝疾患治療剤 | |
JPH04244081A (ja) | 1,4−ジヒドロピリジン誘導体およびそれを有効成分とするアレルギー性または炎症性疾患治療剤 | |
JPS6229588A (ja) | ピラゾロ〔4,3−d〕ピリミジン誘導体 | |
JPH07119225B2 (ja) | フェノキシプロピルアミン誘導体およびこれを含有する抗潰瘍剤 |